HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $58 price target.
Read original at benzingaStocks · News reference
Kodiak Sciences Enrols First Patients In Global Phase 3 ALTO Trial Evaluating KSI-501 In Patients With Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edemaPALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 8:45 PM
- Checked
- Aug 10, 2026, 8:45 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Kodiak Sciences Q2 EPS $(1.05) Misses $(0.95) Estimate
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.95) by 10.53 percent. This is a 1.94 percent decrease over losses of $(1.03) per share from
Read original at benzinga8-K filing — Kodiak Sciences Inc. (KOD)
Filed: 2026-08-13 AccNo: 0001193125-26-349107 Size: 309 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar